ArticleMedical oncology (Northwood, London, England)2012
Reciprocal expression of survivin and SMAC/DIABLO in primary breast cancer.
Article in Medical oncology (Northwood, London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 9 citations in OpenAlex.
- ILP-2: A New Bane and Therapeutic Target for Human Cancers.Frontiers in oncology · 2022Review
- Dysregulated Expression of Apoptosis-Associated Genes and MicroRNAs and Their Involvement in Gastric Carcinogenesis.Journal of gastrointestinal cancer · 2021Observational
- Specificity Protein 1: A Protein With a Two-Sided Role in Ischemic Stroke.Frontiers in cellular neuroscience · 2021Review
- Coexpression of Smac/DIABLO and Estrogen Receptor in breast cancer.Cancer biomarkers : section A of Disease markers · 2021Article
- Dysregulation of the intrinsic apoptotic pathway mediates megakaryocytic hyperplasia in myeloproliferative neoplasms.Journal of clinical pathology · 2016Article
- CDK4 inhibition and doxorubicin mediate breast cancer cell apoptosis through Smad3 and survivin.Cancer biology & therapy · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is an intimate relation between disturbance in survivin and SMAC/DIABLO expressions and cancer formation in many tissues; however, this was not confirmed in the primary breast cancer. The aim of this study was to evaluate the relationship between survivin and SMAC/DIABLO mRNA expressions in primary breast cancer using RT-PCR and their relationship to some of the risk factors (age, family history, breast-feeding, use of contraceptive pills and hormonal receptors). Breast cancer tissues were studied for the detection of the mRNA expression of survivin and SMAC/DIABLO. This was done by qualitative reverse transcription-polymerase chain reaction (RT-PCR). SMAC/DIABLO mRNA was detected by RT-PCR only in 1 sample in breast cancer tissues (6.25%). However, it was expressed in 16 out of 25 (64%) of the benign tumor tissues (P=0.00). In contrast, survivin mRNA was highly expressed in breast cancer tissues, 36 out of 48 (75%) (P=0.00), while its expression was very low in benign tumor tissues, only 1 out of 37 (2.7%) (P=0.00). Expressions of SMAC/DIABLO and survivin were significantly reciprocal in breast cancer and benign tumor tissues. SMAC/DIABLO inhibits apoptosis of breast cancer cells by suppression of survivin. These two genes probably form an important link in the signaling pathway of formation of breast cancer cells, which may be chosen as therapeutic targets in the primary breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.